Article
Present and future of cancer biomarkers
1 Jan 2014
Abstract excerpt
The cancer biomarker field appears to be stagnant. Very few, if any, new cancer biomarkers have been introduced into clinical practice the last 20 years. The reason is that most of the newly discovered cancer biomarkers are inferior in terms of sensitivity and specificity to the classical cancer biomarkers that we currently use. The revolutionary technologies of proteomics, genomics, and other omics did not...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
